Pablo Tenorio Feixas

Specialist in Haematology, made in #HUNSC. Currently Plasma Cell Research Fellow at @KingsCollegeNHS. Granaíno errante.

[Gerardo Rodríguez-Lobato MD, PhD. @DrGerLobato]

Just out! Real-world outcomes of autologous stem cell transplant (ASCT) in #POEMSsyndrome, published in @BMTjournal (@TheEBMT) 🧬 Nearly 3 decades of data. 🔗

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

How I treat plasma cell leukemia @BloodPortfolio #mmsm @utswcancer @UTSWMedCenter @UAMSMyeloma @ldandersonjr @HadidiSamer @ASH_hematology

➡️https://t.co/4MoBX74JPj
🧵

[Pablo Tenorio Feixas @ptenfei]

It is always heartwarming to come across your mentors, even if it is on a screen!

[@sehh_es @sehh_es]

#CLAVESenLLC | Carmen Marrero, del Hospital Universitario Nuestra Señora de Candelaria en #Tenerife, analiza el estudio de fase 2 con pirtobrutinib y obinutuzumab de duración fija en #pacientes con #leucemia linfocítica crónica #LLC no tratados previamente, presentado en #EHA26 #HematoEnRed #SEHHematologia #HEMandNET @gellc

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

#EHA2026 a quad with only 30% any-grade fatigue?

Yes, if you swap out the lenalidomide with iberdomide! Great work by @MyelomaDrKapoor et al.

Neutropenia still something we need to manage aggressively with CELMoDs, although interestingly not much G-CSF needed here.

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

I’ve looked at this #EHA2026 slide 100x but it still always makes me pause.

Unexpected early relapses so scary for patients with myeloma, and historically post-PD OS in FHRMM ≤ 2 years no matter what we do.

Here, off-the-shelf Tx boosted 3-yr PFS from 0% to 77%. Giving these pts a fighting chance for deep & durable remissions 🥹

[Papa Heme @Papa_Heme]

In 2026 we’re still presenting ASCO orals in myeloma with Kd as the control arm

Read the paper by the legendary Dr Mohyuddin.

Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: systematic review - Lancet Haematology https://t.co/E2k9LC5shR

[Ben Derman @bdermanmd]

Excited to welcome everyone to beautiful Chicago for the @ASCO Annual Meeting!
I wanted to highlight some of the most intriguing abstracts in myeloma being presented over the weekend. Let's go!

[Vincent Rajkumar @VincentRK]

Just out: Majestic Majestec-9 results.
#ASCO26 @NEJM

Single agent teclistamab beats standard triplet in relapsed myeloma.

https://t.co/2TeFjBuZSv
@DrOlaLandgren @thanosdimop

[Pablo Tenorio Feixas @ptenfei]

Simply mindblowing!

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

#ASH25 #mmsm @ASH_hematology

Based on multiple requests, updated BCMA therapies with summary of their data

Efficacy data

Note that in Cilta cel ~ 1 out of 4 pts were anti-CD38 refractory

PFS and OS seems best with Tec-Dara
(Impressive hazard ratio)

Hope Tec-Dara will be approved soon (gained FDA Breakthrough Therapy Designation 👏👏)

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

#ASH25 saying it louder for everyone in the back!

If you are starting a bsAb in #MMsm (especially BCMA), don’t wait for patient to die or IgG to drop. Start IgRT now!

Newest case in point: excellent IFM 2021-01 trial. Only 14% Gr3+ infxns despite older pts & CD38 pair!

[Pablo Tenorio Feixas @ptenfei]

@mtmdphd @szusmani Today I happened to see a case proving this. Congratulations for such an excellent piece of work @szusmani!

[Simon Stern @DrSStern]

Important work from @MyMKaiser and his team at the Institute of Cancer Research and @royalmarsdenNHS in this week's @BloodPortfolio.
Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling https://t.co/edPFqsV7AA

[HemaSphere Journal (prelim IF = 11.3) @Hemasphere_EHA]

👉https://t.co/hOpUrBZL4S

This paper show that ibrutinib not only reduces tumor B-cell activity in Waldenström’s macroglobulinemia, but also helps restore T-cell function. The authors suggest combining B-cell targeting with T-call reactivation may offer new treatment options.

[Mohamad Mohty @Mohty_EBMT]

What to expect at #ASH25 in multiple myeloma ? By @TheIACH
https://t.co/fhqMK9FVTr

[Blood Journals Portfolio @BloodPortfolio]

Results support talquetamab as a B-cell sparing treatment to allow preservation of key elements of humoral immunity for patients with RRMM. Read in Blood Advances: https://t.co/qf8Vc5UsuH

[Pablo Tenorio Feixas @ptenfei]

Exploring CAR T outcomes in larger RRMM cohorts with prior ASCT was long overdue!

Definitely a must‑read for the weekend 👏🏼⬇️

[Andrew Portuguese, MD @AJPortuguese]

🧵1/
A single-center report suggested prior ASCT may worsen ide-cel outcomes in RRMM. We tested this in a much larger cohort: 805 U.S. pts s/p ide-cel in the @CIBMTR registry. @RahulBanerjeeMD @drjgauthier @emilyliangmd @fredhutch

🚨 @BloodPortfolio: https://t.co/rNyyVuewTS

[Pablo Tenorio Feixas @ptenfei]

@scocmem @NatRevClinOncol @OncoAlert @tompowles1 @b_szabados @PGrivasMDPhD @shilpaonc @AmandaNizamMD @DrChoueiri @DrYukselUrun @neerajaiims @drenriquegrande @DrRishabhOnco @myESMO @ASCO Great job, congratulations!👏🏼👏🏼

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

🎵 Should I stay or should I go? [on BCMA bispecifics]

Thanks @AjHematology for featuring US #MMsm Consortium work.

Delayed responses most likely if MR by D30 (i.e., on way to ≥PR) or if SD but not lymphopenic. If so, continued bsAb therapy may be more worth the infxn risks!

[Siim Land @siimland]

Exercise is known to be good for us, but how much exercise and is there something like too much exercise?

Exercise is often seen to have a J-shaped curve with mortality risk - not enough is bad but too much is also harmful (PMID: 26187713)

How much is optimal then?⬇️⬇️

[Vincent Rajkumar @VincentRK]

Trials like AQUILA are great examples to study the design, conduct, and interpretation of randomized trials. #MedTwitter

You may see experts argue about how to interpret the trial and what level of benefit will justify practice change. Thats a good thing. But whatever the case is, for those interested in clinical research studying trials like AQULA in detail will be of value.

When a trial is designed, you have no control over the outcome. The outcome of a trial doesn’t make a trial good or bad. But it’s whether it was designed, conducted, and reported fairly.

The AQUILA trial manuscript and the supplemental material have a lot of information we thought clinicians and investigators will need. You can also find in detail discussion of the data from the ODAC hearing.

Im glad to highlight this trial which has today led to the FDA approval of daratumumab for high risk smoldering myeloma. It was already approved in July for this indication in Europe. https://t.co/3hC2E6sPIi